SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:2045 7634 OR L773:2045 7634 srt2:(2021)"

Sökning: L773:2045 7634 OR L773:2045 7634 > (2021)

  • Resultat 1-10 av 15
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Chen, Dongfeng, et al. (författare)
  • RAG1 co-expression signature identifies ETV6-RUNX1-like B-cell precursor acute lymphoblastic leukemia in children
  • 2021
  • Ingår i: Cancer Medicine. - : John Wiley & Sons. - 2045-7634. ; 10:12, s. 3997-4003
  • Tidskriftsartikel (refereegranskat)abstract
    • B-cell precursor acute lymphoblastic leukemia (BCP-ALL) can be classified into subtypes according to the genetic aberrations they display. For instance, the translocation t(12;21)(p13;q22), representing the ETV6-RUNX1 fusion gene (ER), is present in a quarter of BCP-ALL cases. However, around 10% of the cases lack classifying chromosomal abnormalities (B-other). In pediatric ER BCP-ALL, rearrangement mediated by RAG (recombination-activating genes) has been proposed as the predominant driver of oncogenic rearrangement. Herein we analyzed almost 1600 pediatric BCP-ALL samples to determine which subtypes express RAG. We demonstrate that RAG1 mRNA levels are especially high in the ETV6-RUNX1 (ER) subtype and in a subset of B-other samples. We also define 31 genes that are co-expressed with RAG1 (RAG1-signature) in the ER subtype, a signature that also identifies this subset of B-other samples. Moreover, this subset also shares leukemia and pro-B gene expression signatures as well as high levels of the ETV6 target genes (BIRC7, WBP1L, CLIC5, ANGPTL2) with the ER subtype, indicating that these B-other cases are the recently identified ER-like subtype. We validated our results in a cohort where ER-like has been defined, which confirmed expression of the RAG1-signature in this recently described subtype. Taken together, our results demonstrate that the RAG1-signature identifies the ER-like subtype. As there are no definitive genetic markers to identify this novel subtype, the RAG1-signature represents a means to screen for this leukemia in children.
  •  
3.
  • Han, HD, et al. (författare)
  • Erratum
  • 2021
  • Ingår i: Cancer medicine. - : Wiley. - 2045-7634. ; 10:20, s. 7441-7441
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
4.
  • Han, Hedong, et al. (författare)
  • Prevalence, trends, and outcomes of atrial fibrillation in hospitalized patients with metastatic cancer : findings from a national sample
  • 2021
  • Ingår i: Cancer Medicine. - : John Wiley & Sons. - 2045-7634. ; 10:16, s. 5661-5670
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Epidemiological evidence regarding the link between cancer and atrial fibrillation (AF) are limited and outcomes of metastatic cancer comorbid with AF need to be elucidated.Objective: This study aims to evaluate the prevalence, temporal trends, and outcomes of AF in hospitalized metastatic cancer patients.Methods: The National Inpatient Sample (NIS) database was used to identify adult patients with metastatic tumors from 2003 to 2014. We analyzed the trends in AF prevalence, in-hospital mortality, total cost, length of stay (LOS), and comorbidities pertaining to metastatic cancer. Multivariable-adjusted models were used to evaluate the association of AF with clinical factors, in-hospital mortality, total cost, and LOS.Results: Among 2,478,598 patients with metastatic cancer, 8.74% (216,737) were diagnosed with AF. The proportion of comorbid AF increased from 8.28% in 2003 to 10.06% in 2014 (p < 0.0001). Older age, white race, male, Medicare, higher income, larger hospital bed size, and urban teaching hospital were associated with higher AF occurrence. Among primary tumor sites, lung cancer experienced the highest odds of AF compared to other cancers. Patients with metastasis to lymph node and respiratory organ had higher odds of AF. In metastatic cancer, AF was associated with higher in-hospital mortality (odds ratio: 1.48; 95% confidence interval: 1.43-1.54), 18% longer LOS, and 19% higher cost.Conclusions: AF prevalence in metastatic cancer continues to increase from 2003 to 2014. AF is linked to poorer prognosis and higher healthcare resource utilization. As the population ages, optimal preventive and treatment management strategies are needed for metastatic cancer comorbid with AF.
  •  
5.
  • Huang, Wuqing, et al. (författare)
  • Psychiatric disorders in offspring of childhood or adolescent central nervous system tumor survivors : a national cohort study
  • 2021
  • Ingår i: Cancer Medicine. - : Wiley. - 2045-7634. ; 10:2, s. 675-683
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Children experience a higher risk of psychiatric problems when their parents are diagnosed with cancer. However, the psychological effect among offspring who are born after parental cancer diagnosed in childhood or adolescence is unknown. We aimed to investigate the risk of psychiatric disorders in children of survivors with childhood or adolescent central nervous system (CNS) tumors.METHODS: By combining several nationwide Swedish registers, we identified all children who had at least one parent previously diagnosed with CNS tumor below the age of 20. Five children without parental CNS tumor were randomly selected for the matching. Cox proportional hazards model was used to calculate hazard ratios (HRs) with 95% confidence interval (CI).RESULTS: The incidence rate of psychiatric disorders was 8.46 per 1000 person-years in children of CNS tumor survivors, whereas the rate was 7.47 in the matched comparisons, yielding an adjusted HR of 1.10 (95% CI = 0.94, 1.28). Boys of survivors had a higher risk of psychiatric disorders (adjusted HR = 1.29, 95% CI = 1.04, 1.59). The risk of the specific types of psychiatric disorders in children of tumor survivors was comparable with that in the matched comparisons, except for mental retardation. Children of survivors experienced 2.36 times higher risk of mental retardation (95% CI = 1.21, 4.58), mainly of mild mental retardation (adjusted HR = 2.99, 95% CI = 1.40, 6.38).CONCLUSION: Children of survivors with CNS tumor in early life did not experience a significantly increased risk of overall psychiatric disorders, with the exception of an elevated risk of mental retardation that was mainly mild.
  •  
6.
  • Jiang, Xia, et al. (författare)
  • ITGB4 as a novel serum diagnosis biomarker and potential therapeutic target for colorectal cancer
  • 2021
  • Ingår i: Cancer Medicine. - : Wiley. - 2045-7634. ; 10:19, s. 6823-6834
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose To develop new and effective biomarkers for the diagnosis of colorectal cancer (CRC). Experimental design The serum expression of ITGB4 (49 CRC and 367 HC) was detected by enzyme-linked immunosorbent assay (ELISA), and its diagnostic value was analyzed using the receiver operating characteristic (ROC) curve. The sensitivity and specificity of ITGB4 in CRC diagnosis were calculated through statistical analysis. The optimal clinical cutoff value was calculated using the Youden index, and diagnostic efficacy was analyzed in a larger serum sample (98 CRC and 1631 non-CRC). The expression of ITGB4 was measured by CyTOF (cell experimental technology) at the single-cell level, and characteristics were analyzed using viSNE and SPADE TREE. Results Serum ITGB4 and CEA levels were significantly higher in CRC patients than in HC and non-CRC patients. The use of serum ITGB4 levels for the diagnosis of CRC has a high sensitivity (79%) but not high specificity when the clinical cutoff value was 0.70 ng/mL. However, the optimal cutoff value was 1.6 ng/mL with 86.2% specificity and 52.0% sensitivity, and the diagnostic efficacy was greatly improved with high specificity (82.0%) and sensitivity (71.4%) when combined with CEA. ITGB4 expression characteristics were measured and related to the expression of EpCAM, Ck8/18, and perforin at the single-cell level. Single-cell analysis showed that cell clusters with low expression of CK8/18 and ITGB4 were more sensitive to 5FU and radiotherapy (RT). Conclusions ITGB4 is an effective diagnostic serum biomarker and a potential therapeutic target for CRC.
  •  
7.
  • Jochems, Sylvia, et al. (författare)
  • Waist circumference and a body shape index and prostate cancer risk and mortality
  • 2021
  • Ingår i: Cancer Medicine. - : Blackwell Publishing. - 2045-7634. ; 10:8, s. 2885-2896
  • Tidskriftsartikel (refereegranskat)abstract
    • We recently found a negative association between body mass index (BMI) and the risk of localised prostate cancer (PCa), no association with advanced PCa, and a positive association with PCa‐specific mortality. In a 15% subpopulation of that study, we here investigated the measures of abdominal adiposity including waist circumference (WC) and A Body Shape Index (ABSI) in relation to PCa risk and mortality. We used data from 58,457 men from four Swedish cohorts to assess WC and ABSI in relation to PCa risk according to cancer risk category, including localised asymptomatic and symptomatic PCa and advanced PCa, and PCa‐specific mortality. Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). During, on average, 10 years of follow‐up, 3290 men were diagnosed with PCa and 387 died of PCa. WC was negatively associated with the risk of total PCa (HR per 10 cm, 0.95; 95% CI 0.92–0.99), localised PCa (HR per 10 cm, 0.93, 95% CI 0.88–0.96) and localised asymptomatic PCa cases detected through a prostate‐specific antigen (PSA) test (HR per 10 cm, 0.87, 95% CI 0.81–0.94). WC was not associated with the risk of advanced PCa (HR per 10 cm, 1.02, 95% CI 0.93–1.14) or with PCa‐specific mortality (HR per 10 cm, 1.04, 95% CI 0.92–1.19). ABSI showed no associations with the risk of PCa or PCa‐specific mortality. While the negative association between WC and the risk of localised PCa was partially driven by PSA‐detected PCa cases, no association was found between abdominal adiposity and clinically manifest PCa in our population.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 15
Typ av publikation
tidskriftsartikel (15)
Typ av innehåll
refereegranskat (14)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Häggström, Christel (2)
Orho-Melander, Marju (2)
Stocks, Tanja (2)
Lehtinen, M (1)
Paavonen, J (1)
Cao, Y (1)
visa fler...
Pukkala, E (1)
Ivanics, Tommy (1)
Landberg, Göran, 196 ... (1)
Liedberg, Fredrik (1)
Sundquist, Kristina (1)
Wu, C. (1)
Abrahamsson, Jonas (1)
Kovács, Anikó (1)
Stattin, Pär (1)
Helou, Khalil, 1966 (1)
Eriksson, T (1)
Harjula, K (1)
Hokkanen, M (1)
Apter, D (1)
Nieminen, P (1)
Karlsson, Per, 1963 (1)
Cao, Yang, Associate ... (1)
Petaja, T. (1)
Forssell-Aronsson, E ... (1)
Bexe-Lindskog, Elino ... (1)
Järvholm, Bengt (1)
Hesselager, Göran (1)
Sundquist, Jan (1)
He, J (1)
Ji, Jianguang (1)
Guo, W. (1)
Ståhlberg, Anders, 1 ... (1)
Jakola, Asgeir Store (1)
Skoglund, Thomas, 19 ... (1)
Li, Chao (1)
Henriksson, Roger (1)
Fogelstrand, Linda, ... (1)
Nordlund, Jessica (1)
He, Jia (1)
Mårtensson, Inga-Lil ... (1)
Smits, Anja (1)
Sun, Xiao-Feng (1)
Wettergren, Yvonne, ... (1)
Chen, LP (1)
Camponeschi, Alessan ... (1)
May, Anne Maria (1)
Lin, Z (1)
Visser, LNC (1)
Bartek, Jiri (1)
visa färre...
Lärosäte
Uppsala universitet (6)
Karolinska Institutet (6)
Göteborgs universitet (4)
Umeå universitet (3)
Lunds universitet (3)
Örebro universitet (1)
visa fler...
Linköpings universitet (1)
RISE (1)
visa färre...
Språk
Engelska (15)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (11)
År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy